http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
CytomX Therapeutics Announces Publication of First-in-Human Data for CX-2029 in Clinical Cancer Research
-
CytomX Therapeutics to Present at Jefferies Virtual Healthcare Conference
-
CytomX Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update
-
CytomX Therapeutics to Announce First Quarter 2021 Financial Results on May 6, 2021
-
CytomX Therapeutics Announces New Employment Inducement Grants
-
CytomX Therapeutics to Host Virtual Investor Event on April 7, 2021
-
CytomX Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
-
CytomX Therapeutics to Present at Upcoming March Virtual Investor Conferences
-
CytomX Therapeutics Announces New Employment Inducement Grant
-
CytomX Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
-
CytomX Therapeutics to Present at Guggenheim Healthcare Talks 2021 Oncology Day
-
CytomX Therapeutics Announces New Employment Inducement Grants
-
CytomX Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
-
CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors
-
CytomX Therapeutics to Present Updates on CX-2009 at 2020 San Antonio Breast Cancer Symposium
-
CytomX Therapeutics to Present at Upcoming Investor Conferences
-
CytomX Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update
-
CytomX Therapeutics Announces Treatment of First Patient in Phase 2 Expansion Study of CX-2029, an Anti-CD71 Probody Drug Conjugate
-
CytomX Therapeutics to Announce Third Quarter 2020 Financial Results
-
CytomX Therapeutics Announces the Planned Retirement of Chief Scientific Officer, W. Michael Kavanaugh, M.D.
-
CytomX Therapeutics Announces New Employment Inducement Grants
-
CytomX Therapeutics to Participate in Upcoming Healthcare Conferences
-
CytomX Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update
-
CytomX Therapeutics to Participate in the 2020 Wedbush PacGrow Healthcare Conference
-
CytomX Therapeutics to Announce Second Quarter 2020 Financial Results
-
CytomX Therapeutics Announces Preclinical Data from Anti-CTLA-4 Probody Therapeutic Programs Presented by Partner Bristol Myers Squibb at AACR Annual Meeting
-
CytomX Therapeutics Clinical Programs Highlighted at American Society of Clinical Oncology ASCO20 Virtual Scientific Program
-
CytomX Therapeutics to Participate at Upcoming Healthcare Conferences
-
CytomX Therapeutics to Host Conference Call and Webcast to Review ASCO ASCO20 Virtual Scientific Program Presentations
-
CytomX Therapeutics (CTMX) Announces Details of Presentations at ASCO
-
CytomX Therapeutics Announces Details of Presentations at the American Society of Clinical Oncology ASCO20 Virtual Scientific Program
-
CytomX Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update
-
CytomX Therapeutics to Present at the 2020 Bank of America Securities Health Care Conference
-
CytomX Therapeutics Announces Presentations at the 2020 American Society of Clinical Oncology Virtual Scientific Program
-
CytomX Therapeutics (CTMX) Names Halley E. Gilbert to Board
-
CytomX Therapeutics Appoints Halley E. Gilbert to Board of Directors
-
CytomX Therapeutics to Announce First Quarter 2020 Financial Results
-
CytomX Therapeutics Announces Milestone Achievement in AbbVie CD71 Partnership and Provides Update on Impact of COVID-19 on Clinical Stage Pipeline
-
CytomX Therapeutics Announces New Employment Inducement Grant
-
Pre-Open Movers 03/24: (GSAT) (NVAX) (CTMX) Higher; (MIST) (BXRX) (HOTH) Lower (more...)
-
CytomX Therapeutics (CTMX), Astellas Enter Collaboration to Develop Probody T-Cell
-
CytomX Therapeutics and Astellas Announce Strategic Collaboration to Develop Probody® T-Cell Engaging Bispecific Therapies for Treatment of Cancer
-
CYTOMX THERAPEUTICS ANNOUNCES APPOINTMENT OF CARLOS CAMPOY AS CHIEF FINANCIAL OFFICER
-
CytomX Therapeutics Announces New Employment Inducement Grant
-
CytomX Therapeutics Announces Full-Year 2019 Financial Results and Provides Business Update
-
CytomX Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference
-
Bristol-Myers Squibb (BMY), CytomX Therapeutics (CTMX) Begin Randomized Ph.2 Cohort Expansion in Ongoing Phase 1/2a Clinical Trial of Anti-CTLA-4 Probody Therapeutic BMS-986249
-
Bristol-Myers Squibb Advances CytomX Therapeutics’ Anti-CTLA-4 Probody Therapeutic BMS-986249 into Randomized Cohort Expansion (Part 2a) of Ongoing Clinical Trial
-
CytomX Therapeutics to Announce Fourth Quarter 2019 Financial Results
-
CytomX Announces Appointment of Lloyd A. Rowland Jr. as General Counsel

